Results 231 to 240 of about 43,229 (277)

Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders†‡

Hepatology, 2009
Merimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has shown antiviral activity in nonresponders with chronic hepatitis C (CHC) when combined with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV).
Vinod K, Rustgi, William M, Lee, Eric, Lawitz, Stuart C, Gordon, Nezam, Afdhal, Fred, Poordad, Herbert L, Bonkovsky, Leif, Bengtsson, Gurudatt, Chandorkar, Matthew, Harding, Lindsay, McNair, Molly, Aalyson, John, Alam, Robert, Kauffman, Shahin, Gharakhanian, John G, McHutchison   +15 more
openaire   +2 more sources

Pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis C.

2005
Pegylated interfernon and ribavirin are recently used in treatment of chronic hepatitis C. Non.pegylated interferon and ribavirin were also used in same purpose. This meta -analysis is trieing to reveal which of these two combiations is more effective.
Štimac, Davor, Šimin, Marija
openaire   +2 more sources

Pegylated Interferon-α2a and Ribavirin versus Pegylated Interferon-α2b and Ribavirin in Chronic Hepatitis C

Drugs, 2013
Results of trials and meta-analyses comparing pegylated interferon (PEG-IFN)-α2a and PEG-IFN-α2b for the treatment of chronic hepatitis C are conflicting.Our objective was to determine which PEG-IFN (α2a or α2b), in association with ribavirin, is the most effective for the treatment of chronic hepatitis C by performing an updated meta-analysis.MEDLINE (
Nicolas, Flori, Natalie, Funakoshi, Yohan, Duny, Jean-Christophe, Valats, Michael, Bismuth, Dimitri, Christophorou, Jean-Pierre, Daurès, Pierre, Blanc   +7 more
openaire   +2 more sources

Pegylated interferons.

Reviews in gastroenterological disorders, 2002
Interferon therapy for chronic hepatitis C is not a cure, but it is able to decrease the viral load and may decrease the risk of complications (e.g., cirrhosis, liver failure, liver cancer). Pegylation of the interferon increases the amount of time the interferon remains in the body by increasing the size of the interferon molecule. Increasing molecule
openaire   +1 more source

Interaction of PEGylated interferon-beta with antibodies to recombinant interferon-beta

International Immunopharmacology, 2018
Because PEGylated molecules exhibit different physicochemical properties from those of the parent molecules, PEGylated interferonβ-1a (pegIFNβ-1a) may be able to be used with retained bioactivity in Multiple Sclerosis (MS) patients who have previously developed neutralizing antibodies (NABs) to recombinant interferonβ (rIFNβ).
Francesca, Gilli, Adrianna L, De La Torre, Darlene B, Royce, Andrew R, Pachner   +3 more
openaire   +2 more sources

Emerging strategies for pegylated interferon combination therapy

Nature Clinical Practice Gastroenterology & Hepatology, 2007
Several advances afford promise for improving the management of hepatitis C virus (HCV) infection. Current therapies primarily target the immune system; the now proven ability to culture the entire virus in vitro could ultimately facilitate the identification of therapies directly targeting viral replication.
openaire   +2 more sources

Pegylated interferons

Journal of Drug Evaluation, 2004
Raymond D'Souza, Graham Foster
openaire   +1 more source

Treatment with Interferons (including Pegylated Interferons) in Patients with Hepatitis B

Seminars in Liver Disease, 2004
Studies of 4 to 6 months of treatment with interferon for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B virus (HBV) infection have shown clearance of HBeAg to be higher in treated patients than it is in controls by approximately 25%. These results are considerably better than those with antiviral agents.
openaire   +2 more sources

Pegylated interferons: chemical and clinical differences

Alimentary Pharmacology & Therapeutics, 2004
SummaryPegylated interferon therapy for the treatment of chronic hepatitis C virus provides significant increases in sustained virological response rates compared with standard interferons. Two pegylated interferons are now available and are used in conjunction with ribavirin to maximize response rates in infected patients.
openaire   +1 more source

Interferon-γ: teammate or opponent in the tumour microenvironment?

Nature Reviews Immunology, 2021
Creg J Workman, Dario A A Vignali
exaly